TOGA Podcast
39 episodes - English - Latest episode: 2 months ago -Join TOGA to learn more about lung cancer.
Podcasts with leading experts.
Patient Interviews.
Trial updates.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Lung Cancer Nurses: Essential, Beneficial and a Key Link In Lung Cancer Screening
April 22, 2024 02:00 - 35 minutes - 32.9 MBLung Cancer Support Nurse - Lung Foundation Australia Quit Centre | Homepage Lung Cancer Screening Program: Early Detection Saves Lives (thoraciconcology.org.au) Lung Cancer Optimal Care Pathway
Underutilisation of Radiotherapy in Lung Cancer Treatment
March 27, 2024 03:50 - 24 minutes - 22.3 MBRadiation therapy can be a very effective treatment for lung cancers, with 77% of patients indicating for radiation therapy in their disease trajectory. Yet, only 40% of patients with lung cancer in NSW receive radiation therapy. In this podcast, Professor Shalini Vinod, Assoc Professor Mei-Ling Yap, and Dr Clare Bajraszewski discuss why radiation therapy is underutilised in lung cancer, what this means for patients, and potential solutions to address this. This episode's host are: Profe...
Revolutionising Lung Cancer Healthcare with AI: Unlocking the Future
February 28, 2024 10:02 - 30 minutes - 28.3 MBArtificial intelligence (AI) is transforming medicine. Lung Cancer healthcare professionals are interested in the use of AI in radiology, particularly in early diagnosis leading to better patient outcomes. In this podcast we will explore how AI can aid in early detection, accurate interpretation of imaging scans and reduce diagnostic errors. This episode is joined by Associate Professor Michael Franco, a dual trained in medical oncology and palliative care and also the digital health director...
Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer
December 15, 2023 01:45 - 29 minutes - 27.1 MBIn this TOGA Podcast the speakers discuss Antibody Drug Conjugates (ADCs) – An Emerging Treatment Platform in Lung Cancer. The discussion explores the different molecules and mechanisms of drugs currently available, trial results and the subsequent place of ADCs in the Lung Cancer. Furthermore, our guests expand upon the management of patients receiving these drugs. A/Prof Melissa Moore, Medical Oncologist at St Vincent’s Hospital Melbourne, is joined in this conversation by fellow medica...
Lung cancer Screening and Moving from Concept to Roll Out
October 31, 2023 22:00 - 35 minutes - 32.4 MBThis TOGA Podcast discusses Lung cancer Screening and Moving from Concept to Roll Out. The conversation explores the International Lung Cancer Screening Trial and overseas experience of recruitment, the challenges of reaching different population groups, some of whom stand to benefit most from the LCSP, and what it will mean for healthcare workload. The discussion explores the role of Federal and State jurisdictions in the management of the program. A/Prof Emily Stone, Head of Thoracic Me...
Early Recovery After Surgery - Guidelines and Multidisciplinary Considerations
October 06, 2023 03:00 - 38 minutes - 35.6 MBThis TOGA Podcast discusses strategies for enhancing patients’ recovery from lung cancer resection in light of new and emerging data for new peri-operative therapies that improve survival. The conversation explores the guidelines available, the changing landscape for the patient with neoadjuvant and adjuvant management options, and the multidisciplinary considerations to optimise the care of patients. Dr Jazmin Eckhaus, a thoracic surgeon from The Austin, Melbourne, is joined by A/Prof Emil...
Nature and nurture: lung cancer risk and implications for future screening
August 10, 2023 08:00 - 37 minutes - 34.8 MBThis TOGA Podcast discusses the data surrounding air pollution and lung cancer. The discussion delves into Nature and nurture and lung cancer risk and implications for future screening. Associate Professor Tom John, Medical Oncologist from Peter MacCallum Cancer Centre, is joined by Professor Charles Swanton, The Group Leader at the Cancer Therapeutics Laboratory at the London Research Institute and Medical Oncologist from University College in London, Associate Professor Venessa Chin, a Medi...
Operability in Stage III NSCLC
July 04, 2023 14:00 - 31 minutes - 28.6 MBIn this TOGA Podcast, we discuss what defines operability in locally advanced stage III NSCLC. A/Professor Tim Clay, Medical Oncologist from St John of God Subiaco and Rockingham General is joined by Professor Lucy Morgan, Board Chair of the Lung Foundation of Australia and Respiratory Physician from Concord & Nepean Hospitals; A/Professor Phillip Antippa, Cardiothoracic surgeon and the Head of Thoracic Surgical Services at the Royal Melbourne Hospital and the VCCC and also Dr Qurrat van den ...
NSCLC and KRAS Mutations
June 06, 2023 04:00 - 20 minutes - 18.5 MBIn this TOGA Podcast, Australian medical oncologist, Associate Professor Chee Lee, St George Hospital, Kogarah, is joined by medical oncologist Dr Tristan Barnes, Royal North Shore Hospital, Sydney, and Dr Alex Davis, PhD candidate and medical oncologist at Chris O’Brien Lifehouse, Sydney. They discuss treatment of patients with non-small cell lung cancer with KRAS mutations, the role of co-mutations, and biomarkers that are negative predictors of response. Furthermore, the speakers give an u...
Treatment Considerations in ALK-Positive NSCLC
April 21, 2023 14:00 - 22 minutes - 20.2 MBIn this TOGA Podcast, Australian medical oncologist Dr Jenny Lee at Chris O’Brien Lifehouse, Sydney, is joined by medical oncologist Professor Nick Pavlakis, from Royal North Shore Hospital in Sydney and Lisa Briggs, Stage IV lung cancer survivor, Author, Osteopath and Exercise Physiologist who provides her own personal experience after being diagnosed with ALK+ non-small cell lung cancer in 2014. They discuss treatment of patients with non-small cell lung cancer with ALK mutations, the lates...
Celebrating Female Leadership in Medical Research
March 08, 2023 07:00 - 31 minutes - 29.1 MBIn this TOGA Podcast, and on International Women’s Day 2023, we celebrate female leadership in medical research. We explore the challenges and success pathways across different career stages for women who work in medical oncology and clinical research. Associate Professor Prunella Blinman, head of the medical oncology department at Concord Hospital and past chair of the Medical Oncology Group of Australia, is joined by Assistant Professor Narjust Florez, Associate Director of the Cancer Care ...
Brain metastases in NSCLC
February 23, 2023 02:00 - 25 minutes - 23 MBRecent studies in NSCLC patients with ALK or EGFR mutations and brain metastases, demonstrated greater benefit from the use of specific targeted therapies. In this Podcast, Associate Professor Paul Mitchell, Medical Oncologist from the Olivia Newton-John Cancer Centre, is joined by Dr Fiona Hegi-Johnson, Radiation Oncologist, Peter MacCallum Cancer Centre in Victoria, and Dr Dasantha Jayamanne, Radiation Oncologist, Genesis Care and Royal Northshore Hospital in NSW to discuss the management o...
NGS panels in lung cancer
December 20, 2022 01:00 - 36 minutes - 33.8 MBIn this Podcast, Dr Malinda Itchins, Medical Oncologist at Royal North Shore Hospital, Co-Chair of the Advanced Non-Small Cell Lung Cancer Group for TOGA and the Lung Cancer Chair of COSA, is joined by Professor Stephen Fox, Director of Pathology and Head of the Molecular Pathology Laboratory at the Peter MacCallum Cancer Centre in Melbourne Victoria and Professor Michael Millward, Medical Oncologist and Cancer Council Professor of Clinical Cancer Research School of Medicine, University of We...
Lung Cancer Screening and its impact on patient care in Australia
December 07, 2022 14:00 - 25 minutes - 23.6 MBIn the latest TOGA Podcast, Gavin Wright discusses Lung Cancer Screening and its impact on patient care in Australia, accessibility and practicalities of the MSAC recommendation for the lung cancer screening program. He is joined by A/Prof Emily Stone, Dept of Thoracic Medicine and Lung Transplantation, St Vincent's Hospital Sydney and A/Prof Nicole Rankin, Head, Evaluation and Implementation Science Unit Melbourne University and Ms Paula Nelson Thoracic Liaison Nurse/Lung Cancer Nurse at the...
The Management of Stage III NSCLC
October 31, 2022 23:30 - 21 minutes - 19.3 MBWelcome to the Thoracic Oncology Group of Australasia Podcast series. Associate Professor Shankar Siva, Radiation Oncologist and current Cancer Council Victoria Colebatch Fellow who leads the SABR program at Peter MacCallum Cancer Centre discusses The Management of Stage III NSCLC in this podcast. Shankar is joined by Associate Professor Rachel Wong, Deputy Director of Oncology - Eastern Health, Adjunct Clinical Assoc Professor - Monash University and Clinical Research Fellow – WEHI and also...
The Changing Course of Outcomes in Early Stage NSCLC: Surgical and Respiratory Medicine Considerations
October 12, 2022 03:30 - 32 minutes - 29.4 MBWelcome to the Thoracic Oncology Group of Australasia Podcast series. In this Podcast, we discuss early NSCLC management and treatment, particularly in light of how immunotherapy will impact surgical and respiratory medicine as the landscape evolves with new data. Dr Melissa Moore Medical Oncologist from St Vincent’s Melbourne and the TOGA Education Chair, is joined by Dr Katharine See, Director and Head of the Respiratory Medicine at the Northern Hospital, Melbourne and Mr Naveed Alam, Thor...
Cardiotoxicity and Radiation Therapy - Considerations for Lung Cancer
September 01, 2022 19:12 - 23 minutes - 21.3 MBFor lung cancer patients, the benefits of treatment and potential for cure must always be balanced with risk. Cardiotoxicity is considered a short and long term risk from treatment for lung cancer, but this varies between patients. New radiotherapy techniques, lower doses of radiotherapy and supporting cardiovascular treatments can minimise the risk of cardiotoxicity. Monitoring for cardiac complications is becoming an important aspect of survivorship care, and may require collaboration betw...
Accelerating Progress in Oncogene-driven Lung Cancer
August 09, 2022 02:00 - 28 minutes - 26 MBDeme Karikios, Medical Oncologist and Director of Clinical trials at Nepean Cancer Care Centre in Sydney is joined by Wanda Cui, Medical Oncologist from the Peter MacCallum Cancer Centre in Melbourne and Chris Karapetis, Head of the Department of Medical Oncology and Director of Clinical Research at the Flinders Medical Centre in Adelaide.
Access to Molecular Diagnostics and Treatments Across ANZ: The Past, Present, Future
July 24, 2022 04:00 - 27 minutes - 24.9 MBThe identification of molecular subtypes of non-squamous NSCLC continues to grow, spurring the development of targeted therapies designed to target these mutations and prevent the growth of the cancer. People with advanced NSCLC that possess one of these ‘actionable’ mutations and can access targeted treatments can live for many years with very manageable side effects. However, the technology to identify these actionable mutations in a single test and the targeted treatments are not yet acce...
Practical smoking cessation advice for health care providers
May 30, 2022 07:50 - 34 minutes - 62.9 MBIn this TOGA Podcast, we discuss smoking cessation in the face of smoking-related stigma and nihilism. Dr Henry Marshall, Associate Professor and Clinical Academic Fellow, UQ Thoracic Research Centre and Thoracic Physician, The Prince Charles Hospital Queensland is joined by Professor Christine Paul: Behavioural Scientist at the University of Newcastle and School of Medicine and Public Health Dr. Matt Steliga: Chair of The IASLC Tobacco Control and Smoking Cessation Committee and Surgical On...
Consider Every Trial as a TeleTrial
April 30, 2022 11:45 - 19 minutes - 35.4 MBBarriers and facilitators and a unique insight into the patient benefits are discussed between Alexandra, patient advocate, teletrials participant and lung cancer survivor, Sabe Sabesan, medical oncologist from the ICON Cancer Centre in Townsville and co-chair of the Australian Teletrial program and the initial teletrials pilot in 2017-2020, and Craig Underhill, medical oncologist from Border Medical Oncology and Haematology in Albury/Wodonga. Incentive funding and harmonising governance req...
EGFR Update: Improving Outcomes in EGFR-Mutated Non-Small-Cell Cancer
March 29, 2022 17:10 - 26 minutes - 24 MBWelcome to the Thoracic Oncology Group of Australasia Podcast series. Today Rachel Roberts-Thomson, Medical Oncologist from Queen Elizabeth Hospital in Adelaide, discusses Improving Outcomes in EGFR-Mutated Non-Small-Cell Lung Cancer . Rachel is joined byVenessa Chin from St. Vincent’s Hospital in Sydney & Angeline Low who has her own personal experience with EGFR lung cancer . EGFR mutations are identified in approximately 15% of NSCLC patients. Efficacious, PBS-reimbursed first line treat...
The need for a National Clinical Quality Registry in Lung Cancer
February 22, 2022 07:54 - 17 minutes - 16.2 MBThe first TOGA Podcast for 2022 is about the need for a national clinical quality registry in lung cancer. A/Professor Emily Stone, the Deputy Chair of TOGA, is a Respiratory Physician, Senior Staff Specialist and Head of Thoracic Medicine within the Department of Thoracic Medicine and Lung Transplantation at St Vincent’s Hospital Sydney. She is a conjoint Senior Lecturer at the University of New South Wales and the Chair of the St Vincent’s Hospital Lung Cancer Multidisciplinary Team. Emily...
ALK treatment considerations in NSCLC
December 08, 2021 09:10 - 29 minutes - 26.9 MBWelcome to the Thoracic Oncology Group of Australasia Podcast series. Today Mal Itchins, Medical Oncologist from Royal North Shore Hospital discusses ALK therapy choices & considerations when treating ALK NSCLC. Mal is joined by Steven Kao, Medical Oncologist from the Chris O’Brien Lifehouse and Lisa Briggs who has her own personal experience with ALK lung cancer having been diagnosed in 2014, when only limited treatment options were available We have seen rapid transformation in treating A...
Stigma and Nihilism In Lung Cancer : A Call to Action
November 23, 2021 00:20 - 36 minutes - 33.6 MBIn this TOGA Podcast and in recognising Lung Cancer Awareness month 2021, Mel Moore, TOGA Education Chair and Medical Oncologist at St Vincent’s Hospital Melbourne, discusses the importance of treating lung cancer patients with respect, dignity and withholding the often associated judgement. The internal guilt and the pain caused by a diagnosis of lung cancer is amplified by the stigma that exists in society today, including the medical profession. The societal view that lung cancer is self-i...
Challenging the Lung Cancer Stigma
November 08, 2021 13:41 - 30 minutes - 27.9 MBIn this Podcast, Briony Scott discusses the stigma often associated with a diagnosis of lung cancer with Danielle and Terri – both diagnosed with lung cancer and managing the impact on their lives. They also explore self-stigma, family implications, cultural and social behaviours and systemic beliefs.
The Value of Comprehensive Genomic Profiling in Lung Cancer
October 17, 2021 18:36 - 24 minutes - 22.8 MBDrugs that target cancer gene mutations or rearrangements have improved outcomes for patients with many different cancers, including lung cancer, melanoma, and others . The challenge is being able to identify these genomic changes in a timely and efficient manner. Next-generation sequencing (NGS) based tumour comprehensive genomic profiling (CGP) that detects a wide range of genomic aberrations is one method being utilized to match patients to relevant targeted therapies against several onco...
Inflammation And Its Impact On The Development & Treatment Of Lung Cancer
September 24, 2021 01:05 - 23 minutes - 21.6 MBInflammation plays an important role in pathogenesis, development and progression of lung cancer. Widespread literature exists on the prognostic impact of tumor-related factors, whereas host-related factors have not been deeply evaluated to date. Inflammatory indicators could play a vital role in assisting Medical Oncologists to identify which patients are considered at a higher probability of unfavourable prognosis and probably worse toxicity, justifying an appropriate management plan in ad...
Optimising Diagnosis & Treatment Pathways For Lung Cancer Patients
July 30, 2021 17:24 - 28 minutes - 26.2 MBDelays in diagnosis are one of the main factors associated with reduced survival rates for lung cancer patients. Clinical guidelines have been implemented in some countries to standardize the diagnosis process, better define the time from diagnosis to the beginning of treatment, and to improve clinical results in lung cancer. In Australia, periods of 14 days from the initial referral of the GP to the first specialty consultation, and also from diagnosis to the first treatment are recommended...
Long Term Survivorship: Thriving with Metastatic Lung Cancer
June 24, 2021 01:55 - 22 minutes - 20.3 MBWelcome to the Thoracic Oncology Group of Australasia Podcast series. This TOGA Podcast focuses on thriving with lung cancer and overcoming the challenges associated with long term survivorship and lung cancer. The past decade has seen significant advances in the management of metastatic NSCLC with the advent of multiple targeted therapies, immunotherapy approaches and combination approaches and associated improvements in survival outcomes for patients. There is an emerging cohort of patie...
Women and Lung Cancer: The Rising Tide
May 14, 2021 09:06 - 22 minutes - 20.6 MBCigarette smoking is by far the greatest cause for lung cancer. But the proportion of lung cancer in patients who have never smoked before is on the rise. In this podcast, Melissa Moore and Lucy Morgan discuss the increase in lung cancer diagnoses for young women who have never smoked before.
Practical Perspectives: Shifting the Needle in Small Cell Lung Canceer
April 01, 2021 16:30 - 23 minutes - 21.7 MBWelcome to the Thoracic Oncology Group of Australasia Podcast series. This TOGA Podcast focuses on Small Cell Lung cancer (SCLC) – a type of lung cancer with the poorest prognosis of any lung cancer. SCLC patients make up about 13% of new lung cancer diagnoses that are characterized by early & rapid spread with only modest progress in its treatment over the last decades. Immunotherapy continues to radically change the way we treat many types of lung cancer and today we explore what these tre...
Lung cancer screening works!
March 01, 2021 06:21 - 21 minutes - 19.3 MBLung cancer screening works. Earlier detection of lung cancer presents a vastly different prognosis. Stage I disease has a median 5 year survival of greater than 65%, whereas metastatic disease has a 5 year median survival rate of 15-20%. It is time to shift the perception of a lung cancer diagnosis to that of a treatable cancer with a potential cure, through a combination of early-stage detection, and effective communication that newer treatments offer better survival and QoL. The recently ...
Dreaming of Better Treatments for Mesothelioma
February 16, 2021 07:47 - 18 minutes - 16.9 MBAustralia has one of the highest incidence rates of mesothelioma in the world. Mesothelioma is a form of cancer that most often affects the thin linings of the organs in the chest (pleura) and abdomen (peritoneum). Mesothelioma is closely linked with asbestos exposure either at work or among family members of workers and people living in neighbourhoods near asbestos factories and mines. The risk is lifelong. TOGA, the Thoracic Oncology Group of Australasia, is working to positively change ...
Lung Cancer Careers: Preceptorship Reflections
December 13, 2020 17:47 - 18 minutes - 16.5 MBThe first virtual TOGA Preceptorship enabled 38 Preceptees involving Fellows, Advanced Trainees, Nurses and Patients to come together and discuss the landmark papers in lung cancer and the latest in treatment. A multidisciplinary group including Medical Oncology, Radiation Oncology, Respiratory, Nursing, Palliative Care and Surgery were involved and available to share expertise. Hear from two of the Preceptors - Prunella Blinman and Shankar Siva, and three Preceptees – Anna Lawless, Abhiji...
Cancer won't wait: A Cancer Australia Perspective
November 25, 2020 16:43 - 23 minutes - 21.1 MBDorothy Keefe, CEO of Cancer Australia and Mark Scott discuss the COVID impact on diagnosing and treating lung cancer patients – a 4 week delay in diagnosis makes a difference. The red flag symptoms of lung cancer need increased education, especially for the younger, non-smoking women, who are not always aware that a lung cancer diagnosis is possible. GP awareness and early screening is also important here. We are very good at treating breast cancer, colorectal cancer and prostate cancer – w...
2020 Wrap: Remarkable Progress In Diagnosing & Treating Lung Cancer
November 18, 2020 02:57 - 27 minutes - 25.3 MBRemarkable advances in screening, diagnosing and treating lung cancer are discussed in this Podcast. Associate Professor Nick Pavlakis, Medical Oncologists from Royal North Shore Hospital Sydney and Dr Emily Stone, Respiratory Physician from St Vincent’s Hospital Sydney join TOGA for a conversation about public health measures to ensure the survival increase we are seeing for patients with lung cancer continues to accelerate into this decade. Sponsored with a Takeda Educational Grant.
Redefining Survival In Lung Cancer: Meet Alexandra
November 10, 2020 00:11 - 21 minutes - 20 MBLung cancer is the leading cause of cancer related deaths in Australia, and lung cancer in never smokers is still the seventh leading cause of death. Lung cancer kills more women every year than breast, ovarian and uterine cancers combined even though many seem to think that the only cancer women ever get is breast cancer! More young women are being diagnosed every year who have never smoked – around 1/3 of new diagnoses fit this category for women. Thankfully this statistic is declining. ...
Improving Survival In Oncogene Driven Lung Cancer
November 10, 2020 00:10 - 30 minutes - 27.7 MBJoin us for a conversation with internationally recognized Medical Oncologists and researchers, Professor Ben Solomon & Associate Professor Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing. Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib...